Roche: share price stands out, Deutsche Bank in support
At 10:20 a.m., the Swiss biopharmaceutical group's shares were up by around 1%, while the SMI was up by 0.5% at the same time.
Deutsche Bank, which had been selling the stock since January 2023, believes that the unfavorable market sentiment surrounding the stock could improve this year thanks to encouraging data in obesity.
In his view, the results unveiled yesterday for CT-388 are sufficiently interesting to embody a credible alternative to competing products from Novo Nordisk and Eli Lilly in a medium/long-term perspective.
According to DB, this factor could help offset more worrying factors, such as the recent failure of the clinical trial in myasthenia gravis, or the growing competition from HD Eylea (Regeneron) on sales of Vabysmo in diabetic macular edema.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction